Tomlinson P R, Wilson J W, Stewart A G
Microsurgery Research Centre, St. Vincent's Hospital, Fitzroy, Victoria, Australia.
Br J Pharmacol. 1994 Feb;111(2):641-7. doi: 10.1111/j.1476-5381.1994.tb14784.x.
1 beta 2-Adrenoceptor agonists may exacerbate asthma by reducing the release of the anti-proliferative and anti-inflammatory molecule, heparin from mast cells in the airway. In this study, the direct effects of the clinically used bronchodilator, salbutamol, on the proliferation of airway smooth muscle cells grown in culture and stimulated with a range of mitogens have been examined. 2 In mitogen-stimulated cells, salbutamol (0.1-100 nM) inhibited [3H]-thymidine incorporation in a concentration-dependent manner. Salbutamol (100 nM) pretreatment reduced the mitogenic responses to thrombin (0.3 u ml-1), epidermal growth factor (EGF) (300 pM) and U46619 (100 nM) by 61.7 +/- 6.1%, 46.9 +/- 13.9% and 57.6 +/- 12.7%, respectively. However, salbutamol pretreatment did not appear to reduce the small mitogenic response to endothelin-1. 3 Increases in [3H]-leucine incorporation in thrombin (0.3 u ml-1)-stimulated cells were reduced by salbutamol (100 nM) by 27.7 +/- 2.8%. Similarly, thrombin (0.3 u ml-1)-stimulated increases in cell number were also inhibited by salbutamol (100 nM) pretreatment. Thus, the effect of salbutamol in decreasing thrombin-induced [3H]-leucine incorporation may, at least in part, be explained by inhibition of cell proliferation. 4 The inhibition of cell proliferation by salbutamol was prevented by pretreatment with either the non-selective beta-adrenoceptor antagonist, propranolol (0.3 microM) or the selective beta 2-adrenoceptor antagonist, ICI 118551 (50 nM). 5. These results indicate that salbutamol, through activation of a beta 2-adrenoceptor, has a direct inhibitory effect on proliferation elicited by the mitogens thrombin, EGF, and U46619. Thus, it seems likely that this direct inhibitory action of Beta2-adrenoceptor agonists would override any indirect action to accelerate airway smooth muscle proliferation. These observations lead us to suggest that Beta2-adrenoceptor agonists exacerbate asthma by mechanisms unrelated to airway smooth muscle proliferation.
β2肾上腺素能受体激动剂可能会通过减少气道中肥大细胞释放抗增殖和抗炎分子肝素而加重哮喘。在本研究中,已检测了临床使用的支气管扩张剂沙丁胺醇对培养的气道平滑肌细胞增殖的直接作用,这些细胞用一系列促有丝分裂原进行刺激。
在促有丝分裂原刺激的细胞中,沙丁胺醇(0.1 - 100 nM)以浓度依赖的方式抑制[3H] - 胸腺嘧啶核苷掺入。沙丁胺醇(100 nM)预处理使对凝血酶(0.3 u/ml)、表皮生长因子(EGF)(300 pM)和U46619(100 nM)的促有丝分裂反应分别降低了61.7±6.1%、46.9±13.9%和57.6±12.7%。然而,沙丁胺醇预处理似乎并未降低对内皮素 - 1的微小促有丝分裂反应。
沙丁胺醇(100 nM)使凝血酶(0.3 u/ml)刺激的细胞中[3H] - 亮氨酸掺入增加减少了27.7±2.8%。同样,沙丁胺醇(100 nM)预处理也抑制了凝血酶(0.3 u/ml)刺激的细胞数量增加。因此,沙丁胺醇降低凝血酶诱导的[3H] - 亮氨酸掺入的作用,至少部分可以通过抑制细胞增殖来解释。
用非选择性β肾上腺素能受体拮抗剂普萘洛尔(0.3 μM)或选择性β2肾上腺素能受体拮抗剂ICI 118551(50 nM)预处理可防止沙丁胺醇对细胞增殖的抑制作用。
这些结果表明,沙丁胺醇通过激活β2肾上腺素能受体,对凝血酶、EGF和U46619等促有丝分裂原引发的增殖具有直接抑制作用。因此,β2肾上腺素能受体激动剂的这种直接抑制作用似乎会超过任何加速气道平滑肌增殖的间接作用。这些观察结果使我们认为,β2肾上腺素能受体激动剂通过与气道平滑肌增殖无关的机制加重哮喘。